Samarghandian Saeed, Azimi-Nezhad Mohsen, Mehrad-Majd Hassan, Mirhafez Seyed Reza
Department of Basic Medical Sciences, Neyshabur University of Medical Sciences, Neyshabur, Iran.
Pharmacology. 2015;96(3-4):112-7. doi: 10.1159/000436975. Epub 2015 Jul 18.
Gentamicin (GEN) is considered as a main aminoglycoside antibiotic medicine. The top therapeutic side effect of GEN is nephrotoxicity. The current research was proposed to determine the protective effect of thymoquinone (TQ) on GEN-induced acute renal failure (ARF).
The rats were divided into 6 groups: sham group, control group, GEN-treated group and the TQ-treated groups. At the end of the research period, the serum blood urea nitrogen (BUN) and creatinine (Cr) were measured. The kidneys were then removed for evaluating malondialdehyde (MDA), reduced glutathione (GSH), interleukins IL-6, IL-10, IL-18 and IL-1β, tumor necrosis factor α (TNF-α), superoxide dismutase (SOD) and glutathione peroxidase (GPx) levels.
GEN induced a raise in the levels of serum Cr, BUN and also the levels of MDA, IL-6, IL-18, IL-1β and TNF-α with decease in GSH, SOD, GPx and IL-10 in the kidney (p < 0.05). The data illustrated that the significant elevation in the levels of serum Cr, BUN, MDA, IL-6, IL-18, IL-1β, TNF-α and also the reduction of GSH, SOD, SOD, GPx, IL-10 in the kidney were ameliorated in the TQ-treated groups versus the untreated group, in a dose-dependent manner (p < 0.05).
The present investigation proposes that TQ may be ameliorated ARF through modulation of the oxidative stress and inflammatory responses.
庆大霉素(GEN)被认为是一种主要的氨基糖苷类抗生素药物。GEN最主要的治疗副作用是肾毒性。本研究旨在确定百里醌(TQ)对GEN诱导的急性肾衰竭(ARF)的保护作用。
将大鼠分为6组:假手术组、对照组、GEN治疗组和TQ治疗组。在研究期结束时,测量血清血尿素氮(BUN)和肌酐(Cr)。然后取出肾脏,评估丙二醛(MDA)、还原型谷胱甘肽(GSH)、白细胞介素IL-6、IL-10、IL-18和IL-1β、肿瘤坏死因子α(TNF-α)、超氧化物歧化酶(SOD)和谷胱甘肽过氧化物酶(GPx)水平。
GEN导致血清Cr、BUN水平升高,同时肾脏中MDA、IL-6、IL-18、IL-1β和TNF-α水平升高,而GSH、SOD、GPx和IL-10水平降低(p<0.05)。数据表明,与未治疗组相比,TQ治疗组血清Cr、BUN、MDA、IL-6、IL-18、IL-1β、TNF-α水平显著升高,肾脏中GSH、SOD、SOD、GPx、IL-10水平降低的情况得到改善,且呈剂量依赖性(p<0.05)。
本研究表明,TQ可能通过调节氧化应激和炎症反应来改善ARF。